A peer-reviewed journal that offers evidence-based clinical information and continuing education for dentists.

Biopharmaceutical Industry Leaders Call for Principled Approach to COVID-19 Vaccines and Therapies


In a letter to the biopharmaceutical industry, CEOs from Ovid Therapeutics, Nkarta Therapeutics, Global Blood Therapeutics, Biotechnology Innovation Organization, Acorda Therapeutics, GlycoMimetics, Alnylam Pharmaceuticals, and Alkermes released a list of five principles they assert the industry should follow to ensure the effective assessment of data and evaluation of efficacy regarding COVID-19 therapies and vaccines. The principles include:

  • Conducting clinical trials in adherence to best practices
  • Publishing data in peer-reviewed journals or respected scientific sources, not press releases
  • Ensuring the United States Food and Drug Administration remains a non-political regulatory body free from outside influence
  • Introducing new therapies only when sufficient data support their use
  • Eliminating the politicization of COVID-19 therapies and vaccines

Read the letter here.

Leave A Reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy